Cancer of unknown primary: the hunt for its elusive tissue-of-origin - is it time to call off the search?
- PMID: 40615718
- DOI: 10.1038/s41416-025-03073-7
Cancer of unknown primary: the hunt for its elusive tissue-of-origin - is it time to call off the search?
Abstract
Cancer of Unknown Primary (CUP) is an heterogenous group of metastatic cancers, for which the primary site cannot be identified despite thorough diagnostic work-up. Whilst it is a relatively rare entity, its aggressive nature, together with the paucity of effective treatments, mean it has a disproportionately high mortality rate. Advances in genomic profiling have driven research in the area, but despite this, therapeutic options and prognosis remain poor. For many years, the primary focus in CUP has been improving identification of the tissue-of-origin (TOO), with the hope that site-specific therapy will improve survival outcomes. However, the lack of conclusive evidence to support this, as well as an emerging paradigm shift in how cancers should be classified, has reignited the debate surrounding the importance of TOO. Here, we provide a comprehensive review of the ongoing relevance of TOO, within both the CUP and wider oncology landscape.
© 2025. The Author(s).
Conflict of interest statement
Competing interests: NC has received consulting fees from Roche Pharmaceuticals, Servier and REDX Pharmaceuticals; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Roche Pharmaceuticals; support for attending meetings and/or travel from Roche Pharmaceuticals; research funding to research team from AstraZeneca, Orion, F. Hoffmann-La Roche Ltd, Taiho, Novartis, Starpharma, Bayer, Eisai, UCB, RedX Pharmaceuticals, LOXO-oncology, Avacta, Boehringer Ingelheim, Merck and Tarveda Therapeutics; participated in data safety monitoring board or advisory board at Roche Pharmaceuticals and Cancer Research UK. AMC has received support for attending meetings and/or travel from Roche Products Limited, and is a named inventor on a patent registered by “Cancer Research Technology Ltd”. LS and CM declare no potential competing interests.
Similar articles
-
Home treatment for mental health problems: a systematic review.Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150. Health Technol Assess. 2001. PMID: 11532236
-
Interventions targeted at women to encourage the uptake of cervical screening.Cochrane Database Syst Rev. 2021 Sep 6;9(9):CD002834. doi: 10.1002/14651858.CD002834.pub3. Cochrane Database Syst Rev. 2021. PMID: 34694000 Free PMC article.
-
Antidepressants for pain management in adults with chronic pain: a network meta-analysis.Health Technol Assess. 2024 Oct;28(62):1-155. doi: 10.3310/MKRT2948. Health Technol Assess. 2024. PMID: 39367772 Free PMC article.
-
Single-incision sling operations for urinary incontinence in women.Cochrane Database Syst Rev. 2017 Jul 26;7(7):CD008709. doi: 10.1002/14651858.CD008709.pub3. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2023 Oct 27;10:CD008709. doi: 10.1002/14651858.CD008709.pub4. PMID: 28746980 Free PMC article. Updated.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3. PMID: 29271481 Free PMC article. Updated.
References
-
- Cancer Research UK [CRUK]. Cancer of unknown primary (online). Available via: https://www.cancerresearchuk.org/about-cancer/cancer-unknown-primary-cup... (2024). Accessed January 2025.
-
- Qaseem A, Usman N, Jayaraj JS, Janapala RN & Kashif T. Cancer of Unknown Primary: A Review on Clinical Guidelines in the Development and Targeted Management of Patients with the Unknown Primary Site. Cureus (2019). https://doi.org/10.7759/cureus.5552 .
-
- Cancer Research UK [CRUK]. Cancer of unknown primary (online). Available via: https://www.cancerresearchuk.org/about-cancer/cancer-unknown-primary-cup... (2017). Accessed January 2025.
-
- National Institute for Clinical Excellence [NICE]. Metastatic malignant disease of unknown primary origin in adults: diagnosis and management. Available via: https://www.nice.org.uk/guidance/cg104 (2010). Accessed January 2025.
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous